Recent Meta-Analysis on Soy Protein and Heart Health Claims
Introduction to Health Claims and Regulatory Oversight
A recent meta-analysis investigates the heart health claims linked to soy protein and whether these should be retracted. In the United States, the Food and Drug Administration (FDA) plays a crucial role in regulating health claims associated with food products. For any food item to assert a reduction in disease risk, the FDA must first authorize such claims. In 1999, the FDA concluded that consuming soy protein could lower the risk of coronary heart disease by decreasing cholesterol levels.
Reassessment of Soy Protein’s Heart Health Status
However, in 2017, the FDA reevaluated this assertion. Susan Mayne, Ph.D. from the FDA, noted “inconsistent findings concerning the ability of soy protein to lower heart-damaging low-density lipoprotein (LDL) cholesterol” as a significant factor for potentially revoking soy protein’s heart health claim.
New Evidence from a Meta-Analysis
A recent study published in the Journal of the American Heart Association analyzed data from 46 trials focusing on whether soy protein effectively reduces cholesterol levels. The research team conducted a cumulative meta-analysis, systematically adding each study’s results to assess overall evidence trends. Their findings indicate that a diet rich in soy protein can lower total cholesterol levels, specifically reducing “bad” LDL cholesterol by between 4.2 mg/dL and 6.7 mg/dL. Although these reductions are modest, they are statistically significant.
Considerations Regarding the Meta-Analysis
Despite these findings, several factors warrant cautious interpretation.
Limitations of Evidence Compilation
Firstly, while systematic reviews are considered the gold standard in evidence synthesis, the current meta-analysis is not a systematic review. It relies solely on the 46 studies selected by the FDA, which may not encompass the complete body of evidence.
Clinical Relevance of Cholesterol Reductions
Secondly, although the reduction in cholesterol is statistically significant, it may lack clinical significance. The American Heart Association recommends optimal LDL cholesterol levels of 100 mg/dL or lower. For a patient at this threshold, a reduction of 4.2 mg/dL to 6.7 mg/dL translates to a percentage decrease of 4.2% to 6.7%. In contrast, a Cochrane Review on atorvastatin indicated that a 10 mg daily dose achieves a mean reduction of 37.12%.
Soy Protein Consumption Challenges
Lastly, the observed beneficial effects of soy protein were based on a median daily intake of 25g. Achieving this amount may be challenging, as a typical soy burger contains approximately 12g of soy protein, and a cup of soy milk provides only 7g.
Conclusion: The Future of Soy Protein’s Heart Health Claim
The meta-analysis raises questions about the sustainability of soy’s FDA heart health claim status, as the evidence is not definitive. However, soy enthusiasts can take comfort in the findings. While the benefits of soy protein might not be as pronounced as previously believed, it continues to show positive effects on cholesterol levels.
References
1. Statement from Susan Mayne, Ph.D., on proposal to revoke health claim that soy protein reduces risk of heart disease [press release]. Food and Drug Administration, October 30th 2017.
2. Jenkins DJA, Blanco Mejia S, Chiavaroli L, Viguiliouk E, Li SS, Kendall CWC, et al. Cumulative Meta-Analysis of the Soy Effect Over Time. Journal of the American Heart Association. 2019;8(13):e012458.
3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019;73(24):3168-209.
4. Adams SP, Tsang M, Wright JM. Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews. 2015(3).